{"id":"valsartan-and-simvastatin","safety":{"commonSideEffects":[{"rate":"null","effect":"Cough"},{"rate":"null","effect":"Dizziness"},{"rate":"null","effect":"Headache"},{"rate":"null","effect":"Muscle pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Valsartan works by blocking the angiotensin II receptor, which is part of the renin-angiotensin-aldosterone system (RAAS) that regulates blood pressure. By blocking this receptor, valsartan causes blood vessels to relax and dilate, reducing blood pressure. Simvastatin, on the other hand, works by inhibiting the enzyme HMG-CoA reductase, which is involved in the production of cholesterol in the liver. By reducing cholesterol production, simvastatin helps to lower LDL (bad) cholesterol levels and reduce the risk of cardiovascular events.","oneSentence":"Valsartan is an angiotensin II receptor antagonist that blocks the action of angiotensin II, a potent vasoconstrictor, to lower blood pressure. Simvastatin is a statin that inhibits HMG-CoA reductase to reduce cholesterol production in the liver.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:52:40.419Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Hyperlipidemia"}]},"trialDetails":[{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT00385931","phase":"PHASE3","title":"Efficacy and Safety of Valsartan and the Combination of Valsartan and Simvastatin","status":"COMPLETED","sponsor":"Novartis","startDate":"2002-01","conditions":"Hypertension, Hypercholesterolemia, Dyslipidemia","enrollment":412},{"nctId":"NCT04859452","phase":"PHASE1","title":"A Study to Evaluate the DDI of DBPR108 With Metformin,Glibenclamide,Valsartan, or Simvastatin in Healthy Subjects","status":"COMPLETED","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2021-05-26","conditions":"Healthy Subjects","enrollment":56},{"nctId":"NCT04061824","phase":"PHASE4","title":"Clinical Study to Evaluate Adherence Improvement Fixed-dose Combination of Olostar Tab. in Patients With Hypertension and Dyslipidemia","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2016-05-24","conditions":"Hypertension, Dyslipidemias","enrollment":150},{"nctId":"NCT00171093","phase":"PHASE3","title":"A 10-12 Week Study to Evaluate the Safety and Efficacy of 320 mg Valsartan and 80 mg Simvastatin in Combination and as Monotherapies in Treating Hypertension and Hypercholesterolemia","status":"COMPLETED","sponsor":"Novartis","startDate":"2004-09","conditions":"HYPERTENSION, HYPERCHOLESTEROLEMIA","enrollment":369},{"nctId":"NCT00000620","phase":"PHASE3","title":"Action to Control Cardiovascular Risk in Diabetes (ACCORD)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1999-09","conditions":"Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia","enrollment":10251},{"nctId":"NCT00839683","phase":"PHASE1","title":"Pharmacokinetic Drug Interaction Study of Dapagliflozin and Valsartan or Simvastatin in Healthy Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-02","conditions":"Type 2 Diabetes Mellitus","enrollment":24},{"nctId":"NCT00254475","phase":"PHASE3","title":"A Study to Evaluate the Efficacy of Valsartan/Simvastatin Combinations in Patients With Both Essential Hypertension and Hypercholesterolemia","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-11","conditions":"Essential Hypertension, Hypercholesterolemia","enrollment":871},{"nctId":"NCT00738972","phase":"PHASE3","title":"Left Ventricular Hypertrophy Reduction With Statins in Hypertensives Patients (MK0653A-168)","status":"TERMINATED","sponsor":"Fundación Lindavista del Corazón AC","startDate":"2008-01","conditions":"Hypertension","enrollment":12},{"nctId":"NCT00691314","phase":"NA","title":"Efficacy and Safety of Stent Implantation in Symptomatic Extra- and Intracranial Artery Stenosis","status":"COMPLETED","sponsor":"Peking Union Medical College Hospital","startDate":"2008-06","conditions":"Stroke, Transient Ischemic Attack, Atherosclerosis","enrollment":300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Valsartan and simvastatin","genericName":"Valsartan and simvastatin","companyName":"Novartis","companyId":"novartis","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Valsartan is an angiotensin II receptor antagonist that blocks the action of angiotensin II, a potent vasoconstrictor, to lower blood pressure. Simvastatin is a statin that inhibits HMG-CoA reductase to reduce cholesterol production in the liver. Used for Hypertension, Hyperlipidemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}